Search NBIX
NEUROCRINE BIOSCIENCES INC
Nasdaq · CIK 914475
Last close143.18
Daily change+2.47 (1.76%)
10 Years gain+185.39%
Dividends TTM0
Dividend yield0.00%
Fundamental Analysis
NBIX · STANDARD
SIC 2836 · Biological Products, (No Diagnostic Substances) · Fiscal year end 1231
Fundamental
68.7Momentum
63.8Acceleration
63.8Confidence
77.0Annual Revenue17
Quarterly Revenue73
Annual CFO15
Balance SheetAvailable
RankingEligible
Score Breakdown
Growth24.0 / 25
Quality7.8 / 25
Capital Efficiency18.4 / 20
Balance Sheet15.0 / 15
Shareholder Economics0.0 / 10
Forward Indicators0.0 / 5
Signals
Operating leverageOperating margin improved by 2.7507 percentage points.
Strong operating leverageOperating income is growing faster than revenue while operating margin expands.
Warnings
Receivables anomaly · MEDIUMAccounts receivable growth is materially above revenue growth.
Inventory anomaly · MEDIUMInventory growth is materially above revenue growth.
Possible growth trap · HIGHRevenue growth is high, but quality indicators are deteriorating.
Key Metrics
Revenue Growth TTM41.55%OK
Revenue CAGR 3Y24.32%OK
Gross Margin97.54%OK
Operating Margin22.41%OK
FCF Marginn/aMISSING
FCF Growthn/aINSUFFICIENT_HISTORY
ROIC22.84%OK
Incremental Operating Margin 3Y21.12%OK
Net Debt / CFOn/aNOT_MEANINGFUL
Diluted Share Growth 1Y1.66%OK
SBC / Revenuen/aMISSING
SBC / FCFn/aNOT_MEANINGFUL
Financial History
| Period | Revenue | Gross Profit | Operating Income | CFO | FCF | Gross Margin | Op Margin | FCF Margin | ROIC | Shares |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025 FY Dec 31, 2025 | $2.86B | $2.81B | $619.10M | $782.70M | $748.70M | 98.18% | 21.64% | 26.17% | 25.56% | 102.5M |
| 2025 FY Dec 31, 2024 | $2.36B | $2.32B | $570.50M | $595.40M | $557.20M | 98.56% | 24.22% | 23.66% | 29.52% | 103.7M |
| 2025 FY Dec 31, 2023 | $1.89B | $1.85B | $250.90M | $389.90M | $361.60M | 97.9% | 13.3% | 19.16% | 19.66% | 101M |
| 2024 FY Dec 31, 2022 | $1.49B | $1.47B | $249.00M | $339.40M | $322.90M | 98.44% | 16.73% | 21.69% | 26.04% | 98.9M |
| 2023 FY Dec 31, 2021 | $1.13B | $1.12B | $102.50M | $256.50M | $233.10M | 98.74% | 9.04% | 20.56% | 18.34% | 97.9M |
Formula Trace
| Metric | Value | Formula | Status | Source |
|---|---|---|---|---|
| Revenue TTM | $3.26B | sum latest 4 fiscal quarters Revenue | OK | 0000914475-26-000037, 0000914475-25-000181 |
| Revenue Growth TTM | 41.55% | Revenue_TTM / Revenue_TTM_1Y_ago - 1 | OK | 0000914475-26-000037, 0000914475-25-000181 |
| Revenue CAGR 3Y | 24.32% | (Revenue_current / Revenue_3Y_ago)^(1/3) - 1 | OK | 0000914475-26-000007 |
| Revenue CAGR 5Y | 22.29% | (Revenue_current / Revenue_5Y_ago)^(1/5) - 1 | OK | 0000914475-26-000007 |
| Gross Profit CAGR 3Y | 24.21% | (GrossProfit_current / GrossProfit_3Y_ago)^(1/3) - 1 | OK | 0000914475-26-000007 |
| Operating Income Growth | 61.36% | OperatingIncome_current / OperatingIncome_prior_year - 1 | OK | 0000914475-26-000037, 0000914475-25-000181 |
| FCF Growth | n/a | FCF_current / FCF_prior_year - 1 | INSUFFICIENT_HISTORY | derived |
| Revenue Growth Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Profit Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Operating Income Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| FCF Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Margin | 97.54% | Gross Profit / Revenue | OK | 0000914475-26-000037, 0000914475-25-000181 |
| Operating Margin | 22.41% | Operating Income / Revenue | OK | 0000914475-26-000037, 0000914475-25-000181 |
| ROIC | 22.84% | NOPAT / Average Invested Capital | OK | 0000914475-26-000037, 0000914475-25-000181 |
| Net Debt / CFO | n/a | Net Debt / CFO | NOT_MEANINGFUL | 0000914475-26-000037 |
| Current Ratio | 1.87x | Current Assets / Current Liabilities | OK | derived |
| Revenue per Diluted Share | $31.25 | Revenue / Diluted Shares | OK | 0000914475-26-000037, 0000914475-25-000181 |
| SBC / FCF | n/a | SBC / FCF | NOT_MEANINGFUL | derived |